Alzheimer's drugs court challenge
A decision by the government's health watchdog to deny Alzheimer's drugs to patients with mild-stage disease is being challenged at the High Court. The National Institute for Health and Clinical Excellence (NICE) ruled the medicines - donepezil, rivastigmine and galantamine - were not cost effective. But critics argue the decision process was flawed and did not take into account the benefits to carers. It is the first time a judicial review has been sought on a NICE decision.
25 Jun 2007
